Tempus AI Hits Major Profit Goal Amidst Rapid Q3 2025 Growth
Tempus AI achieved its 10-year profitability target in Q3 2025, driven by massive 84.7% revenue growth and exceptional performance in its genomics and clinical testing divisions.
/ 5 items
#TEM↓
Canaccord Launches Tempus AI Coverage with $110 Price Target
Canaccord initiates Tempus AI with Buy rating and $110 target, citing strong growth potential from AI-powered oncology testing and genomic profiling services.
Tempus AI and Whitehawk Therapeutics Partner on AI-Driven Cancer Research
Tempus AI and Whitehawk Therapeutics announce multi-year collaboration using AI and real-world data to develop targeted antibody drug conjugate therapies for cancer patients.
Boosting the Fight Against Childhood Cancer with AI
Shares of Tempus AI rose following the executive order promoting the use of AI to develop solutions for pediatric cancer.
Tempus AI's Heart Scan Update Gets FDA Green Light!
Tempus AI's FDA-cleared Pixel update uses AI to analyze heart MRI scans, generating detailed tissue maps to detect hidden issues like fibrosis, helping doctors provide more precise, personalized care.